Unraveiling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia

References

• Rodríguez B, Nani JV, Almeida PGC, et al. Neuropeptides and oligopeptidases in schizophrenia. Neurosci Biobehav Rev. 2020;108:679–693.
   PubMed Web of Science ®Google Scholar
• Nani JV, Fonseca MC, Engi SA, et al. Decreased nuclear distribution nudE-like 1 enzyme activity in an animal model with dysfunctional disrupted-in-schizophrenia 1 signaling featuring aberrant neurodevelopment and amphetamine-supersensitivity. J Psychopharmacol. 2020;34(4):467–477.
   PubMed Web of Science ®Google Scholar
• Bradshaw NJ, Hayashi MA. NDE1 and NDEL1 from genes to (mal)functions: parallel but distinct roles impacting on neurodevelopmental disorders and psychiatric illness. Cell Mol Life Sci. 2017;74(7):1191–1210.
   PubMed Web of Science ®Google Scholar
• Dal Mas C, Nani JV, Noto C, et al. Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia. Schizophr Res. 2019;208:202–208.
   PubMed Web of Science ®Google Scholar
• Gadelha A, Machado MF, Yonamine CM, et al. Plasma Ndel1 enzyme activity is reduced in patients with schizophrenia – a potential biomarker? J Psychiatr Res. 2013;47(5):657–663.
   PubMed Web of Science ®Google Scholar
• Nani JV, Lee RS, Yonamine CM, et al. Evaluation of NDEL1 oligopeptidase activity in blood and brain in an animal model of schizophrenia: effects of psychostimulants and antipsychotics. Sci Rep. 2020;10(1):18513.
   PubMed Web of Science ®Google Scholar
• Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2014;220:223–250.
   PubMedGoogle Scholar
• Peng S, Li W, Lv L, et al. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 2018;26(143):127–136.
   PubMed Web of Science ®Google Scholar
• Jeppesen R, Christensen RHB, Pedersen EMJ, et al. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – a comprehensive systematic review and Meta-analysis. Brain Behav Immun. 2020;90:364–380.
   PubMed Web of Science ®Google Scholar
• Almeida PGC, Nani JV, Oses J, et al. Neuroinflammation and glial cell activiation in mental disorders. Brain Behav Immun – Health. 2020;2:100034.
   Google Scholar
• Kappelmann N, Khandaker GM, Dal H, et al. Systemic inflammation and intelligence in early adulthood and subsequent risk of schizophrenia and other non-affective psychoses: a longitudinal cohort and co-relative study. Psychol Med. 2019;49(2):295–302.
   PubMed Web of Science ®Google Scholar
• Armstrong RA. When to use the bonferroni correction. Ophthalmic Physiol Opt. 2014;34(5):502–508.
   PubMed Web of Science ®Google Scholar
• Piccart E, Courtney NA, Branch SY, et al. Neurotensin induces presynaptic depression of D2 dopamine autoreceptor-mediated neurotransmission in midbrain dopaminergic neurons. J Neurosci. 2015;35(31):11144–11152.
   PubMed Web of Science ®Google Scholar
• Servonnet A, Minogianis EA, Bouchard C, Bédard AM, et al. Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment. Neuropharmacology. 2017;123:10–21.
   PubMed Web of Science ®Google Scholar
• Kamiya A, Tomoda T, Chang J, et al. DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Hum Mol Genet. 2006;15(22):3313–3323.
   PubMed Web of Science ®Google Scholar
• Hayashi MA, Guerreiro JR, Charych E, et al. Assessing the role of endooligopeptidase activity of Ndel1 (nuclear-distribution gene E homolog like-1) in neurite outgrowth. Mol Cell Neurosci. 2010;44(4):353–361.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Mori D, Toyo-Oka K, et al. Complete loss of Ndel1 results in neuronal migration defects and early embryonic lethality. Mol Cell Biol. 2005;25(17):7812–7827.
   PubMed Web of Science ®Google Scholar
• Saito A, Taniguchi Y, Kim SH, et al. Developmental alcohol exposure impairs activity-dependent S-Nitrosylation of NDEL1 for neuronal maturation. Cereb Cortex. 2017;27(8):3918–3929.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gavrilovici C, Chansard M, et al. Ndel1 and reelin maintain postnatal CA1 hippocampus integrity. J Neurosci. 2016;36(24):6538–6552.
   PubMed Web of Science ®Google Scholar
• Kindler J, Lim CK, Weickert CS, et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry. 2020;25(11):2860–2872.
   PubMed Web of Science ®Google Scholar
• Noto C, Maes M, Ota VK, et al. High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry. 2015;16(6):422–429.
   PubMed Web of Science ®Google Scholar
• Rose DR, Careaga M, Van de Water J, et al. Long-term altered immune responses following fetal priming in a non-human primate model of maternal immune activation. Brain Behav Immun. 2017;63:60–70.
   PubMed Web of Science ®Google Scholar
• Jiang NM, Cowan M, Moonah SN, et al. The impact of systemic inflammation on neurodevelopment. Trends Mol Med. 2018;24(9):794–804.
   PubMed Web of Science ®Google Scholar
• Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42(1):193–215.
   PubMed Web of Science ®Google Scholar
• Vancassel S, Capuron L, Castanon N. Brain kynurenine and BH4 pathways: relevance to the pathophysiology and treatment of inflammation-driven depressive symptoms. Front Neurosci. 2018;12:499.
   PubMed Web of Science ®Google Scholar
• Al-Amin MM, Nasir Uddin MM, Mahmud Reza H. Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin Psychopharmacol Neurosci. 2013;11(3):144–151.
   PubMed Web of Science ®Google Scholar
• Yamamori H, Hashimoto R, Ishima T, et al. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;556:37–41.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ishikawa M, Niitsu T, et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PloS One. 2012;7(8):e42676.
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Molendijk ML, Köhler CA, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 2015;13:289.
   PubMed Web of Science ®Google Scholar
• Pillai A, Schooler NR, Peter D, et al. Predicting relapse in schizophrenia: is BDNF a plausible biological marker? Schizophr Res. 2018;193:263–268.
   PubMed Web of Science ®Google Scholar
• Sahu G, Malavade K, Jacob T. Cognitive impairment in schizophrenia: interplay of BDNF and childhood trauma? A review of Literature. Psychiatr Q. 2016;87(3):559–569.
   PubMed Web of Science ®Google Scholar
• Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med. 2019;49(12):1971–1979.
   PubMed Web of Science ®Google Scholar
• Marcos-Pasero H, Aguilar-Aguilar E, Ikonomopoulou MP, et al. BDNF gene as a precision skill of obesity management. Adv Exp Med Biol. 2021;1331:233–248.
   PubMed Web of Science ®Google Scholar
• Maes M, Sirivichayakul S, Matsumoto AK, et al. Increased levels of plasma tumor necrosis factor-α mediate schizophrenia symptom dimensions and neurocognitive impairments and are inversely associated with natural IgM directed to malondialdehyde and paraoxonase 1 activity. Mol Neurobiol. 2020;57(5):2333–2345.
   PubMed Web of Science ®Google Scholar